Safe blood products – PEI develops WHO-reference materials for platelet concentrates
Testing of blood products for pathogenic agents is an important pillar of blood product safety. Researchers of the Paul-Ehrlich-Institut (PEI) have extended the repository of reference strains for the testing of platelet concentrates as part of their role as Collaborating Centre for the World Health Organization by ten bacterial strains.
Mode of action of the vaccine adjuvant flagellin in fusion proteins has been clarified
Fusion proteins consisting of antigens and the bacterial adjuvant flagellin are promising vaccine candidates. They have the protential to induce immune responses in a targeted and reliable manner, thus conveying protection against infectious diseases. In addition, they can favourably influence misdirected immune reactions, for example as part of a treatment against allergies.
Successes and challenges of leukaemia treatment using CAR-T cells – where are we now?
Treatment of leukaemia and lymphomas using genetically modified immune cells of the patient (CAR-T cells) has produced impressive results in clinical trials, especially for the treatment of B-cell malignancies. However, serious adverse events were reported as well, partly with fatal outcome.